Thiobenzoic Acid

Thiobenzoic Acid

SCHEMBL4056513

[Cs+].[O-]C(=S)c1ccccc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.48
CA4 P22748 2/20 0.48
ALDH1A1 P00352 4/20 0.44
MAPT P10636 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
KMT2A Q03164 2/20 0.42
HSP90AA1 P07900 1/20 0.42
GAA P10253 1/20 0.42
CES1 P23141 3/20 0.41
CES2 O00748 2/20 0.41
TSHR P16473 2/20 0.41
DAO P14920 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
POLB P06746 2/20 0.38
CYP3A4 P08684 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiobenzoic Acid SCHEMBL28571982 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL28946274 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL10423562 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL28582374 0.94 CA2 (0.55) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL6890939 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL29374102 0.94 CA2 (0.55) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL6768673 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL20741484 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL22721212 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1
Thiobenzoic Acid SCHEMBL11322372 0.94 CA2 (0.48) CA2CA4ALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507765-A4 METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR ISRAEL INST BIOLOG RES (IL) 2006-11-02 EP claimed
CN-1662506-A Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor ISRAEL INST BIOLOG RES (IL) 2005-08-31 CN claimed
EP-1507765-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) 2005-02-23 EP claimed
WO-2003092580-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) 2003-11-13 WO claimed
EP-4410804-B1 NUCLEIC ACID STRAND CLEAVING METHOD, NUCLEIC ACID STRAND CLEAVING DEVICE, DOUBLE-STRANDED DNA PRODUCTION METHOD, AND DOUBLE-STRANDED DNA PRODUCTION DEVICE JAPAN SCIENCE & TECH AGENCY (JP) 2026-02-18 EP disclosed
US-20250163098-A1 Nucleic Acid Strand Cleaving Method, Nucleic Acid Strand Cleaving Device, Double-Stranded DNA Production Method, and Double-Stranded DNA Production Device JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2025-05-22 US disclosed
EP-4410804-A1 NUCLEIC ACID STRAND CLEAVING METHOD, NUCLEIC ACID STRAND CLEAVING DEVICE, DOUBLE-STRANDED DNA PRODUCTION METHOD, AND DOUBLE-STRANDED DNA PRODUCTION DEVICE Japan Science and Technology Agency (JP) 2024-08-07 EP disclosed
CN-118043333-A Method and apparatus for cutting nucleic acid strand, and method and apparatus for producing double-stranded DNA 国立研究开发法人科学技术振兴机构 2024-05-14 CN disclosed
WO-2023054391-A1 NUCLEIC ACID STRAND CLEAVING METHOD, NUCLEIC ACID STRAND CLEAVING DEVICE, DOUBLE-STRANDED DNA PRODUCTION METHOD, AND DOUBLE-STRANDED DNA PRODUCTION DEVICE 国立研究開発法人科学技術振興機構 2023-04-06 WO disclosed
US-9095565-B2 Methods for treating blood disorders PHOENICIA BIOSCIENCES, INC. (US) 2015-08-04 US disclosed
US-20140301975-A1 Methods for Treating Blood Disorders PHOENICIA BIOSCIENCES INC (US) 2014-10-09 US disclosed
US-8759378-B2 Methods for treating blood disorders PHOENICIA BIOSCIENCES, INC. (US) 2014-06-24 US disclosed
US-20030225055-A1 Processes for the preparation of carbapenem-type antibacterial agents SANKYO COMPANY, LIMITED (JP) 2003-12-04 US disclosed
WO-2003092580-A2 METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) 2003-11-13 WO disclosed
EP-1338596-A1 PROCESS FOR PRODUCING CARBAPENEM-TYPE ANTIBACTERIAL Sankyo Company, Limited (JP) 2003-08-27 EP disclosed
EP-1257558-A1 METHODS FOR SYNTHESIS OF ALPHA-D-GAL (1- 3) GAL-CONTAINING OLIGOSACCHARIDES Alchemia Pty Ltd (AU) 2002-11-20 EP disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
US-6358928-B1 TREATING RESPIRATORY SYSTEM, RHEUMATIC AND GENETIC DISORDERS ENZYME SYSTEMS PRODUCTS 2002-03-19 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed
WO-2001051499-A1 METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES ALCHEMIA PTY LTD (AU) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163098-A1 Nucleic Acid Strand Cleaving Method, Nucleic Acid Strand Cleaving Device, Double-Stranded DNA Production Method, and Double-Stranded DNA Production Device DNASE1, NSUN2, UNG CA2 717/4885CA4 1494/4885ALDH1A1 2979/4885
US-20030225055-A1 Processes for the preparation of carbapenem-type antibacterial agents OXA1L, MRPL21, IRAK1 CA2 2042/4885CA4 1096/4885ALDH1A1 1903/4885
US-20140301975-A1 Methods for Treating Blood Disorders HBB, HBG1, HBG2 CA2 2839/4885CA4 2116/4885ALDH1A1 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.